Profile data is unavailable for this security.
About the company
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
- Revenue in CNY (TTM)5.94bn
- Net income in CNY872.95m
- Incorporated1996
- Employees4.00k
- LocationGuobang Pharma Ltd#60 Xingmei RoadMeizhu Town, Xincang CountySHAOXING 312500ChinaCHN
- Phone+86 57 181396120
- Fax+86 57 181396129
- Websitehttps://www.gbgcn.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Haoyuan Chemexpress Co Ltd | 2.71bn | 294.90m | 15.25bn | 3.58k | 51.52 | 4.90 | -- | 5.63 | 1.40 | 1.40 | 12.85 | 14.67 | 0.504 | 1.10 | 3.98 | 757,880.40 | 5.37 | 5.94 | 7.32 | 7.80 | 48.93 | 45.09 | 10.66 | 11.74 | 1.46 | 7.54 | 0.4102 | 16.95 | 20.75 | 40.89 | 58.17 | 22.38 | 71.42 | -- |
| Zhejiang Medicine Co Ltd | 8.96bn | 1.24bn | 15.52bn | 5.82k | 12.48 | 1.40 | -- | 1.73 | 1.29 | 1.29 | 9.31 | 11.50 | 0.6499 | 2.76 | 5.65 | 1,540,449.00 | 8.19 | 5.31 | 10.15 | 6.93 | 39.47 | 36.97 | 12.60 | 7.68 | 2.01 | -- | 0.0784 | 30.91 | 20.29 | 5.88 | 170.11 | 27.62 | 3.74 | -18.03 |
| Guobang Pharma Ltd | 5.94bn | 872.95m | 16.00bn | 4.00k | 18.23 | 1.93 | -- | 2.69 | 1.57 | 1.57 | 10.68 | 14.80 | 0.5603 | 3.06 | 7.04 | 1,484,531.00 | 8.20 | 9.52 | 10.33 | 12.47 | 24.67 | 27.10 | 14.64 | 14.91 | 2.30 | -- | 0.1038 | 24.76 | 10.12 | 9.15 | 27.61 | 19.94 | -7.08 | -- |
| China Resources Jingzhng Phrmctcl Co Ltd | 4.40bn | 837.30m | 16.01bn | 4.18k | 19.07 | 4.22 | -- | 3.64 | 1.32 | 1.32 | 6.94 | 5.98 | 0.6755 | 3.53 | 11.30 | 1,051,350.00 | 14.12 | 11.45 | 23.31 | 16.72 | 60.96 | 64.04 | 20.91 | 18.23 | 1.33 | -- | 0.0348 | 93.25 | -2.59 | 12.61 | 9.67 | 11.20 | 30.67 | 36.85 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.36bn | 722.87m | 16.02bn | 5.00k | 22.20 | 1.83 | -- | 2.99 | 0.8113 | 0.8113 | 6.07 | 9.84 | 0.493 | 1.97 | 4.84 | 1,070,948.00 | 6.65 | 9.23 | 7.91 | 12.19 | 34.65 | 33.78 | 13.50 | 15.64 | 2.42 | -- | 0.0152 | 39.55 | -6.57 | 20.67 | -41.34 | 20.58 | 22.64 | 8.45 |
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.76bn | 649.83m | 16.22bn | 1.36k | 24.61 | 2.40 | -- | 4.31 | 0.4079 | 0.4079 | 2.35 | 4.18 | 0.3812 | 0.6322 | 3.82 | 2,765,677.00 | 6.59 | 8.38 | 8.99 | 12.03 | 41.12 | 44.95 | 17.28 | 19.72 | 1.35 | -- | 0.2644 | 23.22 | -0.1984 | 9.70 | 536.09 | 6.43 | 34.44 | -6.04 |
Data as of Feb 11 2026. Currency figures normalised to Guobang Pharma Ltd's reporting currency: Chinese Yuan Renminbi CNY
9.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 7.99m | 2.65% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2025 | 4.29m | 1.42% |
| Guolian Fund Management Co. Ltd.as of 30 Jun 2025 | 3.90m | 1.29% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 3.29m | 1.09% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 2.05m | 0.68% |
| HFT Investment Management Co., Ltd.as of 30 Jun 2025 | 1.65m | 0.55% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.56m | 0.52% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2025 | 1.34m | 0.45% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 1.23m | 0.41% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 1.06m | 0.35% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
